Keytruda

Keytruda Indications/Uses

pembrolizumab

Manufacturer:

Merck Sharp & Dohme

Distributor:

Merck Sharp & Dohme
Full Prescribing Info
Indications/Uses
Melanoma: Pembrolizumab (KEYTRUDA) is indicated for the treatment of patients with unresectable or metastatic melanoma. Adjuvant treatment of patients with melanoma with lymph node involvement who have undergone complete resection.
Non-Small Cell Lung Carcinoma: Pembrolizumab (KEYTRUDA) as monotherapy is indicated for the first-line treatment of patients with metastatic non-small cell lung carcinoma (NSCLC) whose tumors express PD-L1 with a ≥50% tumor proportion score (TPS) as determined by a validated test, with no EGFR or ALK genomic tumor aberrations.
Pembrolizumab (KEYTRUDA), in combination with platinum-pemetrexed chemotherapy, is indicated for the first-line treatment of patients with metastatic non-squamous NSCLC.
Pembrolizumab (KEYTRUDA) as monotherapy is indicated for the treatment of patients with advanced NSCLC whose tumors express PD-L1 with a ≥1% TPS as determined by a validated test and who have received platinum-containing chemotherapy. Patients with EGFR or ALK genomic tumor aberrations should have received prior therapy for these aberrations prior to receiving Pembrolizumab (KEYTRUDA).
Head and Neck Cancer: Pembrolizumab (KEYTRUDA), as a single agent or in combination with platinum and 5-fluorouracil (5-FU) chemotherapy, is indicated for the first-line treatment of patients with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC).
Classical Hodgkin Lymphoma: Pembrolizumab (KEYTRUDA) is indicated for the treatment of patients with refractory classical Hodgkin Lymphoma (cHL), or who have relapsed after greater than or equal to 3 prior lines of therapy.
Urothelial Carcinoma: Pembrolizumab (KEYTRUDA) is indicated for the treatment of patients with locally advanced or metastatic urothelial carcinoma who are not eligible for cisplatin-containing chemotherapy.
Pembrolizumab (KEYTRUDA) is indicated for the treatment of patients with locally advanced or metastatic urothelial carcinoma who have received platinum-containing chemotherapy.
Gastric Cancer: Pembrolizumab (KEYTRUDA) is indicated for the treatment of patients with recurrent locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma whose tumors express PD-L1 [Combined Positive Score (CPS) ≥1] as determined by a validated test, with disease progression on or after two or more prior lines of therapy including fluoropyrimidine- and platinum-containing chemotherapy and if appropriate, HER2/neu-targeted therapy.
Treatment of patients with hepatocellular carcinoma (HCC) who have been previously treated with an anti-angiogenic tyrosine kinase inhibitor (TKI).
Esophageal Cancer: Pembrolizumab (KEYTRUDA) is indicated for the treatment of patients with recurrent locally advanced or metastatic esophageal cancer whose tumors express PD-L1 [Combined Positive Score (CPS) ≥10] as determined by a validated test, and who have received one prior line of systemic therapy.
Pembrolizumab (KEYTRUDA) is indicated for the treatment of patients with recurrent locally advanced or metastatic esophageal cancer who have received two or more prior lines of systemic therapy.
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in